Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kow, Chia Siang, Zaidi, Syed Tabish Razi, Hasan, Syed Shahzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152511/
https://www.ncbi.nlm.nih.gov/pubmed/32281055
http://dx.doi.org/10.1007/s40256-020-00406-0
Descripción
Sumario:There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.

Ejemplares similares